Chemical Industry News, Data & Insights
About Us
Sign in
Home
News
Topics
Sectors
Reports
Weekly
Analytics
Regulatory and Compliance Updates news
(page 2)
11 December 2025
Roche Secures CE Mark for Broadest Automated Mass Spectrometry IVD Menu
Roche's automated mass spectrometry platform now offers 39 tests, enhancing lab efficiency and supporting faster, precise diagnoses, including antibiotic monitoring.
10 December 2025
OMV Petrom Advances Romania's Energy Security
Neptun Deep progresses for 2027 gas. Anaconda-1 drilling follows. Onshore exploration continues. Production licenses extended 15 years.
10 December 2025
Holcim Earns CDP "A" Rankings for Climate and Water Leadership
Holcim's climate and water efforts earn CDP "A" rankings, validating its sustainability strategy and progress towards net-zero and nature-positive goals.
9 December 2025
Borouge and Borealis Introduce Recleo: Cost-Effective Recycled Solutions
Recleo offers a global portfolio of recycled polyolefins, enhancing sustainability and compliance with evolving regulations, while ensuring quality and reliability for diverse applications.
9 December 2025
Lilly's Jaypirca Improves Progression-Free Survival in Treatment-Naïve CLL/SLL
Jaypirca reduced disease progression risk by 80% in CLL/SLL patients, showing promising safety and efficacy in a Phase 3 trial, with fewer adverse events compared to chemoimmunotherapy.
9 December 2025
Roche's Gazyva Approved by EU for Lupus Nephritis
Gazyva, combined with MMF, shows superior results in treating lupus nephritis, potentially delaying end-stage kidney disease, based on phase II and III studies.
News type
New Projects and Expansions
New Projects and Expansions
Project Updates and Milestones
Project Updates and Milestones
Mergers, Acquisitions, and Partnerships
Mergers, Acquisitions, and Partnerships
Innovation and Product Development
Innovation and Product Development
Operational Changes and Investments
Operational Changes and Investments
Sustainability and Environmental Initiatives
Sustainability and Environmental Initiatives
Financial Performance and Strategy
Financial Performance and Strategy
Executive Appointments and Governance Changes
Executive Appointments and Governance Changes
Regulatory and Compliance Updates
Regulatory and Compliance Updates
Workforce and Corporate Social Responsibility (CSR)
Workforce and Corporate Social Responsibility (CSR)
Crisis and Risk Management
Crisis and Risk Management
The right choices in the European chemical industry
Save time with
chemXplore Analytics
Learn more
9 December 2025
Roche Introduces CE-Marked PCR Test for Accurate Vaginitis Diagnosis
The new PCR test improves vaginitis diagnosis by detecting bacteria and yeast, using a single swab for faster, accurate results, enhancing healthcare efficiency.
9 December 2025
Borealis and Borouge Introduce Recleo: Cost-Effective Recycled Polyolefins
Recleo offers a global portfolio of recycled polyolefins, enhancing sustainability and meeting regulatory targets with consistent quality and reliable supply.
8 December 2025
Boehringer Ingelheim's JASCAYD® Approved in China for Progressive Pulmonary Fibrosis
JASCAYD® (nerandomilast) gains approval in China for progressive pulmonary fibrosis, offering a new treatment option after five years, based on successful Phase III trials.
8 December 2025
Roche's Columvi Combo Shows Sustained Survival Benefit in Phase III Study
Columvi with GemOx doubles survival in R/R DLBCL patients, approved in 50+ countries, offering a non-transplant treatment option.
8 December 2025
TotalEnergies and NEO NEXT Merge to Form UK's Largest Independent Oil and Gas Producer
TotalEnergies holds 47.5% in NEO NEXT+, enhancing synergies and cash flow with a diverse asset portfolio, producing over 250,000 barrels daily by 2026. Completion expected in H1 2026.
8 December 2025
Evonik Releases EPDs for Building Protection Products
EPDs for PROTECTOSIL® products offer transparency on environmental impact, aiding construction decisions and aligning with future regulatory requirements.
7 December 2025
Genmab's Phase 3 Trial Shows EPKINLY + R2 Benefits in Relapsed Follicular Lymphoma
EPKINLY + R2 reduces disease progression risk by 79% in relapsed follicular lymphoma, with a 95% response rate. FDA-approved, it offers a new second-line treatment option.
6 December 2025
Protagonist and Takeda: Rusfertide's Long-Term Efficacy in Polycythemia Vera
Rusfertide shows sustained hematocrit control and reduced phlebotomy need in polycythemia vera over 52 weeks, with a consistent safety profile.
5 December 2025
Sumisho Realty Management Receives Business Improvement Order
SRM received a business improvement order for compliance issues. Measures are underway to prevent recurrence and strengthen internal controls. Impact on financial results is expected to be limited.
4 December 2025
Merck's EXZOLT CATTLE-CA1 Conditionally Approved by FDA for Screwworm and Tick Control
EXZOLT CATTLE-CA1, a new isoxazoline pour-on, is conditionally approved for screwworm and cattle fever tick control, with a 98-day meat withdrawal period. Available by prescription in 2026.
3 December 2025
FDA Expands Approval for Lilly's Jaypirca in CLL/SLL Treatment
FDA approves Jaypirca for CLL/SLL patients previously treated with covalent BTK inhibitors, offering a new treatment option with proven efficacy and safety.
3 December 2025
Umicore: Slight Increase in Blood Lead Levels Near Hoboken Site
Average blood lead levels near the site rose but stayed within norms. Participation in tests decreased. Umicore continues environmental efforts and encourages more children to join studies.
2 December 2025
Johnson & Johnson's IMAAVY® (nipocalimab) Approved by European Commission for Generalised Myasthenia Gravis
IMAAVY® (nipocalimab) gains EU approval for gMG, showing sustained disease control in adults and adolescents, with consistent safety and tolerability.
2 December 2025
Roche's Point-of-Care Test for Bordetella Infections Gains FDA and CE Approval
The test delivers PCR-accurate results in 15 minutes, differentiating Bordetella species, aiding rapid diagnosis and treatment, crucial for vulnerable groups.
1 December 2025
TotalEnergies and Chevron Expand Offshore Collaboration
TotalEnergies sells 40% of Nigerian exploration licenses to Chevron, enhancing their joint offshore ventures. Completion awaits regulatory approval.
1 December 2025
Uniper Sells Datteln 4 Power Plant to ResInvest Group
Datteln 4, a modern coal plant, was sold as part of EU-mandated structural remedies. It provides electricity, traction power, and district heating in the northern Ruhr area.
28 November 2025
Asahi Kasei's Oita Plant Earns EcoVadis Platinum for Sustainability
The Oita Plant received its second EcoVadis Platinum Medal for top 1% sustainability, excelling in Environment and Labor & Human Rights.
28 November 2025
MAIRE Challenges EuroChem's Unlawful Actions in UK Court Dispute
MAIRE seeks over €700M in damages, citing EuroChem's contract breaches and contempt of UK court orders, while EuroChem turns to Russian courts, defying arbitration agreements.
26 November 2025
Toray Unveils New Bonding Material for Ultra-Thin Semiconductor Wafers
New bonding material enables thinner semiconductor wafers, enhancing AI, NAND, and power semiconductor performance while reducing environmental impact. Mass production set for 2028.
26 November 2025
Novo Nordisk Seeks FDA Approval for Higher Dose of Wegovy 7.2 mg
FDA to review semaglutide 7.2 mg for obesity under expedited program. Phase 3 trial shows 20.7% weight loss. Approval offers new weight management option.
26 November 2025
RWE and Apollo Secure Long-Term Funding for German Grid Expansion
RWE and Apollo form a JV for Amprion's grid expansion, with Apollo investing €3.2 billion. RWE retains control and will reinvest over the next decade.
25 November 2025
Eni Expands Stake in Nigerian Deepwater Block OML 118
Eni's subsidiary NAE acquires an additional 2.5% in OML 118, raising its share to 15%, aligning with its strategy to enhance its upstream portfolio in Nigeria.
21 November 2025
Merck's KEYTRUDA and Padcev Approved by FDA for Bladder Cancer Treatment
FDA approves first PD-1 inhibitor plus ADC regimens for cisplatin-ineligible muscle-invasive bladder cancer, based on KEYNOTE-905 trial results showing significant EFS improvement.
21 November 2025
ORLEN Joins TNFD for Enhanced ESG Transparency
ORLEN adopts TNFD framework to integrate nature-related impacts into ESG reporting, enhancing biodiversity protection and aligning with global best practices.
← Previous
Next →
